References
- James C, Ugo V, Le Couédic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–1148.
- Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355(23):2452–2466.
- Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–1790.
- Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet [Internet]. 2005;365(9464):1054–1061. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15781101
- Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell [Internet]. 2005;7(4):387–397. Available from: http://www.sciencedirect.com/science/article/pii/S1535610805000942
- Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7(9):673–683.
- Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med [Internet]. 2013;369(25):2379–2390. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24325356
- Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med [Internet]. 2013;369(25):2391–2405. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3966280&tool=pmcentrez&rendertype=abstract\nhttp://www.nejm.org/doi/abs/10.1056/NEJMoa1312542
- Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms [Internet]. Blood. 2014;123(24):3714–3719. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24786775
- Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood [Internet]. 2014;123(14):2220–2228. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24478400
- Larsen TS, Pallisgaard N, Møller MB, et al. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis–impact on disease phenotype. Eur J Haematol [Internet]. 2007;79(6):508–515. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17961178
- Barosi G, Rosti V, Bonetti E, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. Plos One [Internet]. 2012;7(4):e35631. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3334973&tool=pmcentrez&rendertype=abstract
- Barosi G. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter. Best Pract Res Clin Haematol [Internet]. 2014;27(2):129–140. Available from: http://www.sciencedirect.com/science/article/pii/S1521692614000450
- Hasselbalch HC. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Leuk Res [Internet]. 2009;33(1):11–18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18632152
- Hasselbalch HC, Larsen TS, Riley CH, et al. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. Curr Drug Targets [Internet]. 2011;12(3):392–419. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21143149
- Frederiksen H, Farkas DK, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood [Internet]. 2011;118(25):6515–6520. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22039256
- Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res [Internet]. 2013;37(2):214–220. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23174192
- Hasselbalch HC. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev [Internet]. 2013;24(2):133–145. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23415024
- Hasselbalch HC, Bjørn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm [Internet]. 2015;2015:1–16. Available from: http://www.hindawi.com/journals/mi/2015/102476/
- Kiladjian JJ, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia [Internet]. 2015 Oct;1–6. Available from: http://www.nature.com/doifinder/10.1038/leu.2015.326
- Hasselbalch HC. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol [Internet]. 2011;4(6):637–655. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22077528
- Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol [Internet]. 2013;6(1):49–58. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23373780
- Hermouet S, Vilaine M. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection? Haematologica. 2011;96(11):1575–1579.
- Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood [Internet]. 2012;119(14):3219–3225. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22318201
- Bjørn ME, Hasselbalch HC. The role of reactive oxygen species in myelofibrosis and related neoplasms. Mediators Inflamm [Internet]. 2015;2015:1–11. Available from: http://www.hindawi.com/journals/mi/2015/648090/
- Kristinsson SY, Landgren O, Samuelsson J, et al. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95:1216–1220.
- Skov V, Larsen TS, Thomassen M, et al. Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol [Internet]. 2011;87(1):54–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21447007
- Skov V, Thomassen M, Riley CH, et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol [Internet]. 2012;40(9):771–780.e19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22659388
- Skov V, Larsen TS, Thomassen M, et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res [Internet]. 2012;36(11):1387–1392. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22877729
- Hasselbalch HC. A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis? Leuk Res [Internet]. 2014;38(2):263–266. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23932394
- Hasselbalch HC, Thomassen M, Riley CH, et al. Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression. Plos One [Internet]. 2014;9(11):e112786. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4232509&tool=pmcentrez&rendertype=abstract
- Marty C, Lacout C, Droin N, et al. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia [Internet]. 2013;27(11):2187–2195. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23558526
- Feenstra JM, Rumi E, Pietra D, et al. Whole exome sequencing reveals clonal evolution ef myeloproliferative neoplasms to acute myeloid leukemia. ASH; 2015. (Abstr. #1626).
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell [Internet]. 2000;100(1):57–70. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0092-8674(00)81683-9\nhttp://www.sciencedirect.com/science/article/B6WSN-4195FC1-5/2/aef1d48431eadea4567b697b1fee0514
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
- Pettersson H, Knutsen H, Holmberg E, et al. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. Eur J Haematol [Internet]. 2014;94(5):152–156. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25039361
- Hasselbalch HC. Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis. Eur J Haematol [Internet]. 2015;94(2):96–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22318201
- Frederiksen H, Farkas DK, Christiansen CF, et al. Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study. Lancet Haematol [Internet]. 2015;2(7):e289–e296. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2352302615000927
- Riley CH, Jensen MK, Brimnes MK, et al. Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α. Blood. 2011;118(8):2170–2173.
- Riley CH, Hansen M, Brimnes MK, et al. Expansion of circulating CD56 bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α. Eur J Haematol [Internet]. 2015;94(3):227–234. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25082025
- Riley CH, Brimnes MK, Hansen M, et al. Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. Eur J Haematol. 2016;97(1):83–92.
- Desterke C, Martinaud C, Ruzehaji N, et al. Inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis. Mediators Inflamm. 2015;2015:1–16. [E–pub ahead of print].
- Hasselbalch HC. Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Rev Hematol [Internet]. 2014;7(2):203–216. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24524202
- Christensen AS, Møller JB, Hasselbalch HC. Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2014;38(4):490–495.
- Farmer S, Horváth-Puhó E, Vestergaard H, et al. Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. Br J Haematol. 2013;163(5):603–610.
- Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European leukemiaNet. J Clin Oncol. 2011;29(6):761–770.
- Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood [Internet]. 2011;118(2):401–408. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21536863
- Johansson P, Mesa R, Scherber R, et al. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leuk Lymphoma. 2012;53:441–444.
- Abelsson J, Andréasson B, Samuelsson J, et al. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk Lymphoma [Internet]. 2013;54(10):2226–2230. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23398206
- Geyer H, Scherber R, Kosiorek H, et al. Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease. J Clin Oncol [Internet]. 2016;34(2):151–159. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.62.9337
- Geyer HL, Dueck AC, Scherber RM, et al. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators Inflamm [Internet]. 2015. [e–pub ahead of print]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26538823
- Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc [Internet]. 2006;81(2):159–166. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16471068
- Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179–3184.
- Elala Y, Lasho TL, Gagnat N, et al. Driver mutations and prognosis in 502 patients with essential thrombocythemia. ASH; 2015. (Abstr. #1599).
- Tefferi A, Lasho TL, Finke C, et al. Targeted next-generation sequencing in polycythemia vera and essential thrombocythemia. ASH; 2015. (Abstr. #354).
- Koschmieder S, Mughal TI, Hasselbalch HC, et al. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia [Internet]. 2016;30(5):1018–1024. doi:10.1038/leu.2016.12
- Spivak JL, Hasselbalch H. Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther [Internet]. 2011;11(3):403–414. Available from: http://informahealthcare.com/doi/abs/10.1586/era.11.10
- Kiladjian JJ, Rain JD, Bernard JF, et al. Long-term incidence of hematological evolution in three french prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32(4):417–421.
- Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29(29):3907–3913.
- Spivak JL. An inconvenient truth. Blood. 2010;115(14):2727–2728.
- Tefferi A, Barbui T. Polycythaemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90(2):162–173.
- Campbell PJ, MacLean C, Beer PA, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood [Internet]. 2012;120(7):1409–1411. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3470936&tool=pmcentrez&rendertype=abstract
- Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia [Internet]. 2013;27(9):1874–1881. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3768558&tool=pmcentrez&rendertype=abstract
- Gangat N, Strand J, Li CY, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007;138(3):354–358.
- Bonicelli G, Abdulkarim K, Mounier M, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol [Internet]. 2013;160(2):251–254. Available from: http://doi.wiley.com/10.1111/bjh.12117
- Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med [Internet]. 1999;340(2):115–126. Available from: http://www.nejm.org/doi/full/10.1056/NEJM199901143400207\nhttp://www.nejm.org/doi/pdf/10.1056/NEJM199901143400207
- Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482–2494.
- Rho YH, Chung CP, Oeser A, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum Internet. 2009;61:1580–1585. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2828265&tool=pmcentrez&rendertype=abstract
- Alexandroff AB, Pauriah M, Camp RDR, et al. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol [Internet]. 2009;161(1):1–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19500102
- Hahn B. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med [Internet]. 2003;349(25):2379–2380.
- Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004;25(1):4–7.
- Lin RJ, Afshar-Kharghan V, Schafer AI. Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. Blood. 2014;124(2):184–187.
- Hasselbalch HC. The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis? Leuk Res. 2014;38(10):1230–1236.
- Estève E, Georgescu V, Heitzmann P, et al. [Multiple skin and mouth squamous cell carcinomas related to long-term treatment with hydroxyurea]. Ann Dermatol Venereol [Internet]. 2001;128(8–9):919–921. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11590345
- BC Cancer Agency Cancer Drug Manual(R). Developed September 1994, revised December 2006 and october 2013 [Internet]. Available from: http://www.bccancer.bc.ca/drug-database-site/DrugIndex/Hydroxyurea_monograph_1Oct2013.pdf
- Kissova J, Ovesna P, Penka M, et al. Second Malignancies in Philadelphia-negative myeloproliferative neoplasms − single-center experience. Anticancer Res. 2014;34:2489–2496.
- Hansen IO, Sørensen AL, Hasselbalch HC. Second malignancies in hydroxyurea and interferon treated Philadelphia-negative myeloproliferative neoplasms. Eur J Haematol. 2017;98(1):75–84.
- Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood [Internet]. 2005;105(7):2664–2670. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15585653
- Bjorkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29(17):2410–2415.
- Hasselbalch HC, Silver RT. Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial? Expert Rev Hematol. 2015;8(4):439–445.
- Snyder AR, Zhou J, Deng Z, et al. Therapeutic doses of hydroxyurea cause telomere dysfunction and reduce TRF2 binding to telomeres. Cancer Biol Ther [Internet]. 2009;8(12):1136–1145. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=19363303&retmode=ref&cmd=prlinks\npapers3://publication/uuid/DBEB4AA0-BCF3-46BC-97B8-C37EAFCE7DEF
- Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12(10):1133–1138.
- King KY, Matatall KA, Shen -C-C, et al. Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells. Exp Hematol [Internet]. 2015;43(10):912–918.e2. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0301472X15001952
- Kong Y, Cui H, Ramkumar C, et al. Regulation of senescence in cancer and aging. J Aging Res. 2011;963172:2011.
- Barosi G. An immune dysregulation in MPN. Curr Hematol Malig Rep [Internet]. 2014;9(4):331–339. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25139710
- Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–2232.
- Mesa R, Miller CB, Mascarenhas JO, et al. History and quality of life in patients with polycythemia vera: results from the MPN landmark survey in the United States. ASH; 2015. (Abstr. #4077).
- Latagliata R, Spadea A, Cedrone M, et al. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. Cancer [Internet]. 2012;118(2):404–409. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21692060
- Birgegard G. Advances and challenges in the management of essential thrombocythemia. Ther Adv Hematol [Internet]. 2015;6(3):142–156. Available from: http://tah.sagepub.com/lookup/doi/10.1177/2040620715580068
- Beauverd Y, Radia D, Cargo C, et al. Pegylated interferon alpha-2a for essential thrombocythaemia during pregnancy, outcome and safety: a case series. Haematologica [Internet]. 2016;101:e182–e184.
- Harrison CN, Robinson SE. Myeloproliferative disorders in pregnancy. Hematol Oncol Clin North Am [Internet]. 2011;25(2):261–275. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-79953042860&partnerID=40&md5=cc9bc2dcded0aa3cc6eb3cc83e3be2ac
- Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood [Internet]. 2008;112(8):3065–3072. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18650451
- Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117(18):4706–4715.
- Gowin K, Thapaliy P, Samuelson J, et al. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica. 2012;97(10):1570–1573.
- Stauffer Larsen T, Iversen KF, Hansen E, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res [Internet]. 2013;37(9):1041–1045. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23827351
- Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood [Internet]. 2013;122(6):893–901. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23782935
- Utke Rank C, Weis Bjerrum O, Larsen TS, et al. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2015 Jun 18. doi:10.3109/10428194.2015.1049171 [E-pub ahead of print].
- Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFN a −2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762–1770.
- Them NCC, Bagienski K, Berg T, et al. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol [Internet]. 2015;90(4):288–294. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25545244
- Verger E, Cassinat B, Dosquet C, et al. Clinical and molecular response to interferon-alfa therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015;126(24):2585–2592.
- Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol [Internet]. 2009;27(32):5418–5424. Available from: http://jco.ascopubs.org/content/27/32/5418.abstract
- Hasselbalch HC, Kiladjian JJ, Silver RT. Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. J Clin Oncol. 2011–2012;29(18):2011.
- Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood [Internet]. 2006;108(6):2037–2040. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16709929
- Silver RT, Hasselbalch HC. Optimal therapy for polycythemia vera and essential thrombocythemia: preferred use of interferon therapy based on phase 2 trials. Hematology. 2016;21:387–391. [E–pub ahead of print].
- Mascarenhas J, Mesa R, Prchal J, et al. Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials. Haematologica. 2014;99(6):945–949.
- Simon R, Blumenthal M, Rothenberg G, et al. The role of nonrandomized trials in the evaluation of oncology drugs. Clin Pharmacol Ther [Internet]. 2015;97(5):502–507. Available from: http://doi.wiley.com/10.1002/cpt.86
- Huang B-T, Zeng Q-C, Zhao W-H, et al. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Leuk Res [Internet]. 2014;38(10):1177–1183. Available from: http://www.lrjournal.com/article/S0145212614001982/fulltext
- Silver RT, Barela A, Lascu E, et al. The effect of initial molecular profile on response to recombinant interferon α (rIFNα-) treatment in early myelofibrosis. Cancer. 2017. Forthcoming.
- Kiladjian JJ, Massé A, Cassinat B, et al. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia [Internet]. 2010;24(8):1519–1523. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20520643
- Mikkelsen SU, Kjær L, Skov V, et al. Safety and efficacy of combination therapy of interferon-alpha2 + JAK1-2 inhibitor in the Philadelphia-negative chronic myeloproliferative neoplasms. Preliminary results from the Danish COMBI-trial - an open-label, single-arm, non-randomized, multicenter study. ASH; 2015. (Abstr. #824).
- Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med [Internet]. 2012;366(9):799–807. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23423753
- Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur J Heart Fail [Internet]. 2012;14(4):423–429. Available from: http://doi.wiley.com/10.1093/eurjhf/hfs017
- Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med [Internet]. 2015;372(5):426–435. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25629741
- Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med [Internet]. 2012;366(9):787–798. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa1110556\nhttp://www.ncbi.nlm.nih.gov/pubmed/22375970
- Harrison C, Verstovsek S, McMullin MF, et al. Janus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? Br J Haematol. 2012;157:426–437.
- Mascarenhas JO, Cross NC, Mesa RA. The future of JAK inhibition in myelofibrosis and beyond. Blood Rev [Internet]. 2014;28(5):189–196. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25043171
- Hsu L, Armstrong AW. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res [Internet]. 2014;2014(283617). Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4027021&tool=pmcentrez&rendertype=abstract
- Ghoreschi K, Gadina M. Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol [Internet]. 2014;23(1):7–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24131352
- Bjørn ME, Hasselbalch HC. The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Clin Case Reports [Internet]. 2015;3(6):499–503. Available from: http://doi.wiley.com/10.1002/ccr3.281
- Wilkins BS, Radia D, Woodley C, et al. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica. 2013;98(12):1872–1876.
- Koehler A, Hubert K, Lange T, et al. JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib. Ann Hematol [Internet]. 2015;94(11):1929–1930. Available from: http://link.springer.com/10.1007/s00277-015-2454-4
- Deininger M, Radich J, Burn TC, et al. The effect of long-term ruxolitinib treatment on JAK2V617F allele burden in patients with myelofibrosis. Blood. 2015;126(13):1551–1555.
- Parampalli Yajnanarayana S, Stübig T, Cornez I, et al. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol Internet. 2015;169(6):824–833. Available from: http://doi.wiley.com/10.1111/bjh.13373
- Keohane C, Kordasti S, Seidl T, et al. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol [Internet]. 2015;171(1):60–73. Available from: http://doi.wiley.com/10.1111/bjh.13519
- Schonberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res [Internet]. 2015;75(11):2187–2199. Available from: http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-14-3198
- Massa M, Campanelli R, Fois G. Reduced frequency of CD4+CD25++CD127low/- FOXp3+ regulatory T-cells in patients with primary myelofibrosis. ASH; 2015. (Abstr. #2809).
- Coussens LM, Werb Z. Inflammation and cancer. Nature [Internet]. 2002;420(6917):860–867. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2803035&tool=pmcentrez&rendertype=abstract
- Mantovani A, Garlanda C, Allavena P. Molecular pathways and targets in cancer-related inflammation. Ann Med. 2010;42(3):161–170.
- Di Bona D, Cippitelli M, Fionda C, et al. Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol. 2006;45(2):271–279.
- Masarova L, Wang W, Newberry KJ, et al. Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis. Blood. 2016;128(6):877–880.
- Bjørn ME, De Stricker K, Kjær L, et al. Combination therapy with interferon and JAK1-2 inhibitor is feasible: proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera. Leuk Res Reports [Internet]. 2014;3(2):73–75. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4216335&tool=pmcentrez&rendertype=abstract
- Vainchenker W, Delhommeau F, Constantinescu SN, et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood [Internet]. 2011;118(7):1723–1735. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21653328
- Hermouet S, Hasselbalch HC, Čokić V. Mediators of inflammation in myeloproliferative neoplasms: state of the art. Mediators Inflamm [Internet]. 2015;2015:1–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26681841
- Silver RT, Vandris K, Goldman JJ. Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. Blood [Internet]. 2011;117(24):6669–6672. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21518929
- Pizzi M, Silver RT, Barel A, et al. Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol [Internet]. 2015;28(10):1315–1323. Available from: http://www.nature.com/doifinder/10.1038/modpathol.2015.93
- Barosi G, Tefferi A, Besses C, et al. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia [Internet]. 2015;29(1):20–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25151955
- Barbui T, Thiele J, Carobbio A, et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood [Internet]. 2012;120(3):569–571. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2012-01-407981
- Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128–5133.
- Barosi G, Vannucchi AM, De Stefano V, et al. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. Leuk Res [Internet]. 2014;38(2):155–160. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24378116
- Xu D, Erickson S, Szeps M, et al. Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood [Internet]. 2000;96(13):4313–4318. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11110707
- Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer [Internet]. 2014;120(4):513–520. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4231215&tool=pmcentrez&rendertype=abstract
- Kiladjian JJ, Harrison C. Myeloproliferative neoplasms and personalized medicine: the perfect match? Haematologica [Internet]. 2015;100(12):1493–1494. Available from: http://www.haematologica.org/cgi/doi/10.3324/haematol.2015.137182